ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

IRWD Ironwood Pharmaceuticals Inc

6.415
-0.145 (-2.21%)
Last Updated: 15:25:16
Delayed by 15 minutes
Share Name Share Symbol Market Type
Ironwood Pharmaceuticals Inc NASDAQ:IRWD NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.145 -2.21% 6.415 6.41 6.42 6.63 6.41 6.55 173,717 15:25:16

Ironwood Pharmaceuticals to Present at the Goldman Sachs 38th Annual Global Healthcare Conference

08/06/2017 9:01pm

Business Wire


Ironwood Pharmaceuticals (NASDAQ:IRWD)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Ironwood Pharmaceuticals Charts.

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the Goldman Sachs 38th Annual Global Healthcare Conference on Thursday, June 15, 2017 at 10:00 a.m. Pacific Time (1:00 p.m. Eastern Time) at the Terranea Resort in Rancho Palos Verdes, California.

A live webcast of Ironwood’s presentation will be accessible through the Investors section of the company’s website at www.ironwoodpharma.com. To access the webcast, please log on to the Ironwood website approximately 15 minutes prior to the start time to ensure adequate time for any software downloads that may be required. A replay of the webcast will be available on Ironwood’s website for 14 days following the conference.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (NASDAQ: IRWD) is a commercial biotechnology company focused on creating medicines that make a difference for patients, building value for our fellow shareholders, and empowering our passionate team. We are commercializing two innovative primary care products: linaclotide, the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC), and lesinurad, which is approved to be taken with a xanthine oxidase inhibitor (XOI) for the treatment of hyperuricemia associated with uncontrolled gout. We are also advancing a pipeline of internally and externally generated innovative product candidates in areas of significant unmet need, including uncontrolled gastroesophageal reflux disease and vascular and fibrotic diseases. Ironwood was founded in 1998 and is headquartered in Cambridge, Mass. For more information, please visit www.ironwoodpharma.com or www.twitter.com/ironwoodpharma; information that may be important to investors will be routinely posted in both these locations.

Ironwood Pharmaceuticals, Inc.Media RelationsTrista Morrison, 617-374-5095Director, Corporate Communicationstmorrison@ironwoodpharma.comorInvestor RelationsMeredith Kaya, 617-374-5082Senior Director, Investor Relationsmkaya@ironwoodpharma.com

1 Year Ironwood Pharmaceuticals Chart

1 Year Ironwood Pharmaceuticals Chart

1 Month Ironwood Pharmaceuticals Chart

1 Month Ironwood Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock